These findings identify TPMD as a first-in-class compound that specifically targets PPARγ acetylation and possesses the potential of developing into a safe insulin sensitizer to treat and prevent T2D and obesity. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.